Safety and Efficacy Study of OMS721 in Patients With Atypical Hemolytic Uremic Syndrome (aHUS)
A Phase 3 Study to Evaluate the Safety and Efficacy of OMS721 for the Treatment of Atypical Hemolytic Uremic Syndrome (aHUS) in Adults and Adolescents
Sponsor: Omeros Corporation
Terminated
Sponsor terminated study
Other terminated trials from Omeros Corporation
- IgA Nephropathy · Phase PHASE3 · Jan 2024
- Huntington's Disease · Phase PHASE2 · Oct 2014
- Intraocular Lens Replacement · Phase PHASE3 · Aug 2014
More terminations from Omeros Corporation
Other Atypical Hemolytic Uremic Syndrome trials with similar outcome
This PHASE3 trial investigates Atypical Hemolytic Uremic Syndrome and Thrombotic Microangiopathies and is currently terminated or withdrawn. Omeros Corporation leads this study, which shows 9 recorded versions since 2018 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
9 versions recorded-
Jan 2026 — Present [monthly]
Terminated PHASE3
Status: Recruiting → Terminated
-
Sep 2024 — Jan 2026 [monthly]
Recruiting PHASE3
-
Aug 2024 — Sep 2024 [monthly]
Recruiting PHASE3
Status: Unknown → Recruiting
-
Jul 2024 — Aug 2024 [monthly]
Unknown PHASE3
Status: Unknown Status → Unknown
-
Jan 2021 — Jul 2024 [monthly]
Unknown Status PHASE3
▶ Show 4 earlier versions
-
Nov 2020 — Jan 2021 [monthly]
Unknown Status PHASE3
Status: Recruiting → Unknown Status
-
Nov 2018 — Nov 2020 [monthly]
Recruiting PHASE3
-
Jun 2018 — Nov 2018 [monthly]
Recruiting PHASE3
-
Aug 2017 — Jun 2018 [monthly]
Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Omeros Corporation
For direct contact, visit the study record on ClinicalTrials.gov .